Neurofibromatoses Type II - Pipeline Review, H1 2018

  • ID: 4529316
  • Report
  • 50 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Beta Pharma Inc
  • Plex Pharmaceuticals Inc
  • MORE
Neurofibromatoses Type II - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type II - Pipeline Review, H1 2018, provides an overview of the Neurofibromatoses Type II (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.

Report Highlights:

This latest pipeline guide Neurofibromatoses Type II - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type II (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase 0 and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Neurofibromatoses Type II (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses Type II (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses Type II (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type II (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type II (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Beta Pharma Inc
  • Plex Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Neurofibromatoses Type II - Overview

Neurofibromatoses Type II - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neurofibromatoses Type II - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neurofibromatoses Type II - Companies Involved in Therapeutics Development

AstraZeneca Plc

Beta Pharma Inc

Lixte Biotechnology Holdings Inc

Plex Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Neurofibromatoses Type II - Drug Profiles

AR-42 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bortezomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FRAX-597 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icotinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0000355 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0001117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0001317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0001982 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neurofibromatoses Type II - Dormant Projects

Neurofibromatoses Type II - Product Development Milestones

Featured News & Press Releases

May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Table 1: Number of Products under Development for Neurofibromatoses Type II, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Universities/Institutes, H1 2018

Table 4: Products under Development by Companies, H1 2018

Table 5: Products under Development by Universities/Institutes, H1 2018

Table 6: Number of Products by Stage and Target, H1 2018

Table 7: Number of Products by Stage and Mechanism of Action, H1 2018

Table 8: Number of Products by Stage and Route of Administration, H1 2018

Table 9: Number of Products by Stage and Molecule Type, H1 2018

Table 10: Neurofibromatoses Type II - Pipeline by AstraZeneca Plc, H1 2018

Table 11: Neurofibromatoses Type II - Pipeline by Beta Pharma Inc, H1 2018

Table 12: Neurofibromatoses Type II - Pipeline by Lixte Biotechnology Holdings Inc, H1 2018

Table 13: Neurofibromatoses Type II - Pipeline by Plex Pharmaceuticals Inc, H1 2018

Table 14: Neurofibromatoses Type II - Pipeline by Recursion Pharmaceuticals Inc, H1 2018

Table 15: Neurofibromatoses Type II - Dormant Projects, H1 2018

List of Figures

Figure 1: Number of Products under Development for Neurofibromatoses Type II, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Targets, H1 2018

Figure 5: Number of Products by Stage and Targets, H1 2018

Figure 6: Number of Products by Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Mechanism of Actions, H1 2018

Figure 8: Number of Products by Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Routes of Administration, H1 2018

Figure 10: Number of Products by Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca Plc
  • Beta Pharma Inc
  • Lixte Biotechnology Holdings Inc
  • Plex Pharmaceuticals Inc
  • Recursion Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll